You are here: Industry Insights > Alphamab

News List

Ascletis Announces Completion of 149 Patient Enrollment and Positive Interim Results of Phase IIb Chronic Hepatitis B Study in China for its Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolim prnasia
July 28, 2021
Ascletis Pharma Inc. today announces the completion of 149 patient enrollment and the positive interim results of Phase IIb study on chronic hepatitis B (CHB) patients in China treated with ASC22 (Envafolimab) -- a first-in-class, subcutaneously ...
Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA prnasia
June 30, 2021
Alphamab Oncology announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to envafolimab (KN035), a recombinant humanized PD-L1 single-domain antibody independently invented by Alphamab Oncology ...
Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021 prnasia
June 07, 2021
Alphamab Oncology announced that data from a Phase II study (KN046-IST-04) of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for pancreatic ductal adenocarcinoma (PDAC) was presented in a poster session at the ASCO 2021.
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021 prnasia
June 07, 2021
Alphamab Oncology announced that data from the Phase II clinical study of the PD-L1/CTLA-4 bispecific antibody KN046 combined with platinum doublet chemotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) is ...
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021 prnasia
June 07, 2021
Alphamab Oncology announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous ...
Poster to Highlight ENVASARC Pivotal Trial of Envafolimab (KN035) will be presented at the 2021 ASCO Annual Meeting prnasia
May 24, 2021
Alphamab Oncology announced the study design of the ENVASARC pivotal trial in the U.S. of Envafolimab (KN035), a recombinant humanized PD-L1 single domain antibody independently invented by Alphamab Oncology, will be presented by Alphamab's partner ...
Alphamab announced PD-L1/CTLA-4 bispecific antibody KN046 will enter new Phase II clinical trial in combination with Pfizer's Inlyta® (axitinib) prnasia
April 29, 2021
Alphamab Oncology announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer to evaluate the efficacy and safety of KN046 in combination with Inlyta® (axitinib) for the first-line treatment of NSCLC.
Alphamab Oncology Presented Clinical Data of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at AACR 2021 prnasia
April 13, 2021
Alphamab Oncology announced that data from phase Ib/II clinical study (clinical trial No.: KN046-203) of PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel for the treatment of patients with metastatic triple-negative breast ...
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study prnasia
December 04, 2020
Ascletis Pharma Inc. announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated. ASC22 (Envafolimab) is a first-in-class ...
Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases pharmafocusasia
January 17, 2019
Ascletis Pharma Inc and Suzhou Alphamab Co., Ltd. (Alphamab) jointly announce today that Ascletis' subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing agreement for .....

Previous page 1 2 Next page